You can buy or sell PLX and other stocks, options, ETFs, and crypto commission-free!
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. Read More The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.
52 Week High
52 Week Low
Yahoo FinanceMar 19
Do Options Traders Know Something About Protalix (PLX) Stock We Don't?
Investors in Protalix BioTherapeutics, Inc. PLX need to pay close attention to the stock based on moves in the options market lately. That is because the May 17, 2019 $2.00 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the oth...
Seeking AlphaMar 18
Protalix BioTherapeutics, Inc. (PLX) CEO Moshe Manor on Q4 2018 Results - Earnings Call Transcript
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Q4 2018 Earnings Conference Call March 18, 2019 8:30 AM ET Company Participants Yossi Maimon - CFO Moshe Manor - CEO Conference Call Participants Ram Selvaraju - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Protalix Full Year 2018 Financial Results and Corporate Update. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to introduce your host for today’s conference, Yossi Maimon, ...
Yahoo FinanceMar 18
Protalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate Update
CARMIEL, Israel, March 18, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced its financial results for the full-year ended December 31, 2018 and provided a corporate update. “Throughout 2018 and into early 2019, we significantly advanced our clinical development...
-$0.05 per share
-$0.03 per share